Movement Alert｜REMEGEN Intraday Decline 5.02%, Ophthalmic Drug RC28-E Registration Apparently Rejected by NMPA

Market Focus07-30

On July 30, REMEGEN fell 5.02% in regular trading, trading at HK$78.5/share, with turnover of HK$131 million. The decline came after news emerged that the company's key ophthalmic pipeline candidate faced a regulatory setback.

According to publicly available information, on July 28 the National Medical Products Administration (NMPA) published drug notification delivery records involving seven drugs, including REMEGEN's RC28-E (Ilifu Pu Alpha Intraocular Injection, acceptance number CXSS2500103). In standard regulatory practice, receipt of such a notification typically indicates that the drug registration application was either not approved or voluntarily withdrawn by the applicant. RC28-E is one of the company's core pipeline assets targeting ophthalmic diseases.

Within the Biotechnology sector, the overall tone was broadly negative. Among peers, INNOVENT BIO fell 3.51%, AKESO fell 2.77%, BEIGENE fell 2.61%, 3SBIO fell 2.46%, and SKB BIO fell 5.1%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118295239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 11:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118295239","market":"hk","top_or_hot":-1,"title":"Movement Alert｜REMEGEN Intraday Decline 5.02%, Ophthalmic Drug RC28-E Registration Apparently Rejected by NMPA","media":"Market Focus","content":"<p><p>On July 30, REMEGEN fell 5.02% in regular trading, trading at HK$78.5/share, with turnover of HK$131 million. The decline came after news emerged that the company's key ophthalmic pipeline candidate faced a regulatory setback.</p><p>According to publicly available information, on July 28 the National Medical Products Administration (NMPA) published drug notification delivery records involving seven drugs, including REMEGEN's RC28-E (Ilifu Pu Alpha Intraocular Injection, acceptance number CXSS2500103). In standard regulatory practice, receipt of such a notification typically indicates that the drug registration application was either not approved or voluntarily withdrawn by the applicant. RC28-E is one of the company's core pipeline assets targeting ophthalmic diseases.</p><p>Within the Biotechnology sector, the overall tone was broadly negative. Among peers, INNOVENT BIO fell 3.51%, AKESO fell 2.77%, BEIGENE fell 2.61%, 3SBIO fell 2.46%, and SKB BIO fell 5.1%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜REMEGEN Intraday Decline 5.02%, Ophthalmic Drug RC28-E Registration Apparently Rejected by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜REMEGEN Intraday Decline 5.02%, Ophthalmic Drug RC28-E Registration Apparently Rejected by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 11:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, REMEGEN fell 5.02% in regular trading, trading at HK$78.5/share, with turnover of HK$131 million. The decline came after news emerged that the company's key ophthalmic pipeline candidate faced a regulatory setback.</p><p>According to publicly available information, on July 28 the National Medical Products Administration (NMPA) published drug notification delivery records involving seven drugs, including REMEGEN's RC28-E (Ilifu Pu Alpha Intraocular Injection, acceptance number CXSS2500103). In standard regulatory practice, receipt of such a notification typically indicates that the drug registration application was either not approved or voluntarily withdrawn by the applicant. RC28-E is one of the company's core pipeline assets targeting ophthalmic diseases.</p><p>Within the Biotechnology sector, the overall tone was broadly negative. Among peers, INNOVENT BIO fell 3.51%, AKESO fell 2.77%, BEIGENE fell 2.61%, 3SBIO fell 2.46%, and SKB BIO fell 5.1%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1118295239","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118295239","pubTimestamp":1785381595,"columns":[{"name":"Policy And Regulatory","id":32,"label_key":"policyRegulatory"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, REMEGEN fell 5.02% in regular trading, trading at HK$78.5/share, with turnover of HK$131 million. The decline came after news emerged that the company's key ophthalmic pipeline candidate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"异动预警|REMEGEN盘中下跌5.02%，眼科用药RC28-E注册明显遭NMPA拒绝","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On July 30, REMEGEN fell 5.02% in regular trading, trading at HK$78.5/share, with turnover of HK$131 million. The decline came after news emerged that the company's key ophthalmic pipeline candidate faced a regulatory setback.According to publicly available information, on July 28 the National Medical Products Administration (NMPA) published drug notification delivery records involving seven drugs, including REMEGEN's RC28-E (Ilifu Pu Alpha Intraocular Injection, acceptance number CXSS2500103). In standard regulatory practice, receipt of such a notification typically indicates that the drug registration application was either not approved or voluntarily withdrawn by the applicant. RC28-E is one of the company's core pipeline assets targeting ophthalmic diseases.Within the Biotechnology sector, the overall tone was broadly negative. Among peers, INNOVENT BIO fell 3.51%, AKESO fell 2.77%, BEIGENE fell 2.61%, 3SBIO fell 2.46%, and SKB BIO fell 5.1%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118295239","isCrawlerRequest":true}